Clinical trials: Advanced Intestinal Cancer
Advanced or Recurrent Colorectal Cancer
Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)
The efficacy and safety of panitumumab (Vectibix) in the routine clinical setting will be studied. Specifically, information will be collected on the following as events of interest: skin disorders, interstitial lung disease…
- Trial name
- NCT02089737
- Testing
- Panitumumab
- Volunteers
- 3,091 people
- Sponsor
- Takeda
Colo-rectal Cancer, Colon Cancer
Pre-Operative Treatment in REseCTable COlon CanceR
This is an open-label, randomized, controlled, multicenter, phase III study with two parallel arms. Patients with advanced colon cancer, including the upper third of the rectum, clinically staged cT3-4 and or cN+ (defined as…
- Conditions
- Colo-rectal Cancer, Colon Cancer, Colon Carcinoma
- Trial name
- NCT06899477
- Testing
- mFOLFOXIRI, mFOLFOX-6, CAPOX
- Where
- 28 sites in Germany
- Volunteers
- 714 people
- Sponsor
- Dominik Paul Modest
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Pancreatic Cancer
- Trial name
- NCT00987766
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride, oxaliplatin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Ovarian Neoplasms, Prostatic Neoplasms
A Study of DM002 in Patients With Advanced Solid Tumors
The goal of study： The study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In Part 1, a few participants will receive the lowest dose of study drug.
- Conditions
- Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Colorectal Neoplasms
- Trial name
- NCT06751329
- Testing
- DM002
- Where
- 7 sites in United States, Australia
- Volunteers
- 280 people
- Sponsor
- Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
Cutaneous Melanoma, Non-small Cell Lung Cancer
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
This study will test the safety of a drug called PF-08046049/SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body. It will also study the side effects of this drug.
- Conditions
- Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms
- Trial name
- NCT05571839
- Testing
- PF-08046049
- Where
- 37 sites in United States, Canada and 4 more
- Volunteers
- 41 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Colorectal Cancer, Gastric Cancer
Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers
It is planned to study the effectiveness of low-dose immunotherapy (IT) nivolumab 40 mg for either 2 courses of therapy or 6 courses as preoperative therapy in patients with dMMR/MSI locally advanced CRC.
- Trial name
- NIVO402025 (NCT07542262)
- Testing
- Low-dose nivolumab, Low-dose nivolumab with/without chemotherapy, Low-dose nivolumab combined with chemotherapy
- Where
- Russia
- Volunteers
- 128 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Rectal Neoplasm Malignant
Metabolomics to Predict Treatment Response and Toxicities in Rectal Cancer
Background: Colorectal cancer is the leading cause of cancer-related deaths in Taiwan, with rectal cancer accounting for approximately 27% of all cases.
- Trial name
- NCT06831669
- Testing
- Collecting biospecimens
- Where
- Taiwan
- Volunteers
- 250 people
- Sponsor
- Chang Gung Memorial Hospital
Cancer, Solid Tumor
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
CRLX101 is a nanopharmaceutical comprised of the chemotherapeutic camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer.
- Trial name
- NCT00333502
- Testing
- Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- NewLink Genetics Corporation
Metastatic Colorectal Cancer
Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer
Phase II study of TAS-102 plus bevacizumab switch maintenance therapy in patients with mCRC
- Trial name
- ALEXANDRIA (NCT02654639)
- Testing
- TAS-102, Bevacizumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Georgetown University
Rectal Cancer, Rectal Adenocarcinoma
Advanced Endoscopic Resections for Rectal Neoplasms
This study evaluates how advanced endoscopic resection techniques affect treatment outcomes in adults with rectal cancer. Rectal cancer has traditionally been treated with standard abdominal surgery.
- Conditions
- Rectal Cancer, Rectal Adenocarcinoma, Rectal Adenoma, Rectal Neuroendocrine Neoplasm
- Trial name
- NCT07410767
- Testing
- Endoscopic submucosal dissection, Endoscopic intramuscular dissection
- Where
- Poland
- Volunteers
- 300 people
- Sponsor
- Jagiellonian University
Rectal Cancer
Rosuvastatin in the Treatment of Rectal Cancer
This study will evaluate whether the addition of Rosuvastatin to standard chemoradiation therapy for the treatment of locally advanced rectal cancer may improve the pathological response rate and survival compared to standard…
- Trial name
- NCT02569645
- Testing
- Rosuvastatin
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- AHS Cancer Control Alberta
Colorectal Cancer
The Culture of Advanced/Recurrent/Metastatic Colorectal Cancer Organoids and Drug Screening
The study aims to establish an organoids platform and apply them to screen drugs for advanced/recurrent/metastatic colorectal cancer patients.
- Trial name
- NCT05304741
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chongqing University Cancer Hospital
Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer
Improving Informed Consent for Palliative Chemotherapy
Patients are routinely asked to sign an "informed consent" document prior to starting chemotherapy, indicating they understand the risks and benefits of treatment.
- Conditions
- Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer
- Trial name
- NCT02282722
- Testing
- Investigational informed consent for chemotherapy, Usual, standard-of-care informed consent for chemotherapy
- Where
- 8 sites in United States
- Volunteers
- 216 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Solid Tumor, BRAF V600 Mutation
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
This is a Phase I, First-In-Human, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of ABM-1310 in adult patients with locally…
- Trial name
- NCT04190628
- Testing
- ABM-1310, Cobimetinib
- Where
- 8 sites in United States
- Volunteers
- 53 people
- Sponsor
- ABM Therapeutics Corporation
Colorectal Neoplasms
Acupuncture to Reduce Symptoms of Advanced Colorectal Cancer
This study investigates the effect of acupuncture in reducing symptom distress in adults with advanced colon cancer.
- Trial name
- NCT00034034
- Testing
- Acupuncture
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Colorectal Cancer (CRC)
MRD-Guided Surveillance in Locally Advanced Mid-Low Rectal Cancer (SURVEILLANCE-III)
This study aims to explore the relationship between minimal residual disease (MRD) status and disease recurrence in patients with locally advanced mid-low rectal cancer.
- Trial name
- SURIII (NCT06879899)
- Volunteers
- 139 people
- Sponsor
- Fudan University
Gastric Cancer, Colorectal Cancer
Effect of Multi-modal Intervention Care on Cachexia in Patients With Advanced Cancer Compared to Conventional Management (MIRACLE)
Background Cancer Cachexia (CC) is a multi-factorial process characterized by progressive weight loss, muscle mass and fat tissue wasting, and adversely affecting their quality of life and survival in patients with advanced stage…
- Conditions
- Gastric Cancer, Colorectal Cancer, Pancreatic Cancer, Biliary Tract Cancer
- Trial name
- MIRACLE (NCT04907864)
- Testing
- Multi-modal intervention
- Where
- South Korea
- Volunteers
- 112 people
- Sponsor
- Kil Yeon Lee
Advanced Malignancies, Oncology
Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies
Phase 1/2a Study of RP-001 in participants with Advanced Malignancies
- Conditions
- Advanced Malignancies, Oncology, Colorectal Cancer, Pancreatic Cancer
- Trial name
- NCT07504263
- Testing
- RP-001
- Volunteers
- 66 people
- Sponsor
- Recurv Pharma Inc
Colorectal Neoplasms, Digestive System Diseases
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
The primary objective is to determine the sensitivity and specificity of the Exact Colorectal Cancer (CRC) screening test for colorectal cancer, using colonoscopy as the reference method.
- Conditions
- Colorectal Neoplasms, Digestive System Diseases, Colonic Diseases, Colorectal Cancer
- Trial name
- DeeP-C (NCT01397747)
- Where
- 184 sites in United States, Canada
- Volunteers
- 12,776 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
Locally Advanced or Metastatic Epithelial Tumor
A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors
In phase Ia study, the safety and tolerability of SI-B001 in patients with locally advanced or metastatic epithelial malignancies will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of…
- Trial name
- NCT04603287
- Testing
- SI-B001
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.